Everolimus (Votubia ®) for refractory seizures associated with tuberous sclerosis complex (TSC)

Assessment Status Rapid review complete
HTA ID -
Drug Everolimus
Brand Votubia®
Indication For the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC.
Assessment Process
Rapid review commissioned 19/04/2017
Rapid review completed 26/04/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

The company do not plan to submit a HTA dossier to the NCPE therefore the cost effectiveness of the technology cannot be proven.